Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

HIV Home HBVseq HBV RT Mutations Blast Hits DB Release Notes

HBV RT: BLAST Hits

AuthorsTitleCitationE-value# in HBVDB# in Gb% in HBVDBAnnotation
Horiike (2007) Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences J. Med. Virol. 79 (7), 911-918 (2007) 0 28 28 100 HBVDB

Download amino acid sequences: aligned
Download nucleic acid sequences: aligned or unaligned

AccessionCountryColleDateGBCloneNameGBNoteGenotypeSEMutList
AB195930 Japan:Ehime     genotype C; Japanese patient, BTH case 1, serum 1:before lamivudine C 1 344 134N,170R,223A,267Q,271N
AB195931 Japan:Ehime     genotype C; Japanese patient, BTH case 1, serum 2:after lamivudine, peak of HBV-DNA C 1 344 80I,134N,204I,223A,224V,267Q,271N,332Y
AB195932 Japan:Ehime     genotype C; Japanese patient, BTH case 1, serum 3:after lamivudine, peak of ALT C 1 344 80I,134N,176I,204I,223A,224V,267Q,271N,332Y
AB195933 Japan:Ehime     genotype B; Japanese patient, BTH case 2, serum 1:before lamivudine B 1 344 124N
AB195934 Japan:Ehime     genotype B; Japanese patient, BTH case 2, serum 2:after lamivudine, peak of HBV-DNA B 1 344 80I,91I,122L,124N,127G,204I,222T
AB195935 Japan:Ehime     genotype B; Japanese patient, BTH case 2, serum 3:after lamivudine, peak of ALT B 1 344 80I,91I,122L,124N,127G,204I,222T
AB195936 Japan:Ehime     genotype C; Japanese patient, BTH case 3, serum 1:before lamivudine C 1 344 106C,134S
AB195937 Japan:Ehime     genotype C; Japanese patient, BTH case 3, serum 2:after lamivudine, peak of HBV-DNA C 1 344 55R,80I,106C,134S,163V,204I,267Q
AB195938 Japan:Ehime     genotype C; Japanese patient, BTH case 3, serum 3:after lamivudine, peak of ALT C 1 344 55R,80I,106C,134S,163V,204I,267Q
AB195939 Japan:Ehime     genotype C; Japanese patient, BTH case 4, serum 1:before lamivudine C 1 344 124H,128A,213T,221Y,229V,269L,271H
AB195940 Japan:Ehime     genotype C; Japanese patient, BTH case 4, serum 2:after lamivudine, peak of HBV-DNA C 1 344 55Q,109Q,124H,128A,180M,204V,213T,221Y,229V,269L,271H
AB195941 Japan:Ehime     genotype C; Japanese patient, BTH case 4, serum 3:after lamivudine, peak of ALT C 1 344 55Q,109Q,124H,128A,180M,204V,213T,221Y,229V,269L,271H
AB195942 Japan:Ehime     genotype C; Japanese patient, BTH case 5, serum 1:before lamivudine C 1 344 77F,269L,333Q,337H
AB195943 Japan:Ehime     genotype C; Japanese patient, BTH case 5, serum 2:after lamivudine, peak of HBV-DNA C 1 344 122L,180M,204I,333Q,337H
AB195944 Japan:Ehime     genotype C; Japanese patient, BTH case 5, serum 3:after lamivudine, peak of ALT C 1 344 122L,180M,204I,333Q,337H
AB195945 Japan:Ehime     genotype C; Japanese patient, BTH case 6, serum 1:before lamivudine, 18 bases deletion (nt2848-2865) inpreS1 C 1 344 162V,317A,337H
AB195946 Japan:Ehime     genotype C; Japanese patient, BTH case 6, serum 2:after lamivudine, 45 bases deletion (nt11-55) in preS2 C 1 344 162V,180M,204V,317A,337H
AB195947 Japan:Ehime     genotype C; Japanese patient, BTH case 7, serum 1:before lamivudine C 1 344 267Q,269L,337H
AB195948 Japan:Ehime     genotype C; Japanese patient, BTH case 7, serum 2:after lamivudine, peak of HBV-DNA, 24 bases deletion(nt2850-2873) in pre-S1 C 1 344 55R,204I,267Q,269L,337H
AB195949 Japan:Ehime     genotype C; Japanese patient, non-BTH case 8, serum1: before lamivudine C 1 344 267Q,269L
AB195950 Japan:Ehime     genotype C; Japanese patient, non-BTH case 8, serum2: after lamivudine, peak of HBV-DNA C 1 344 180M,204V,267Q,269L
AB195951 Japan:Ehime     genotype C; Japanese patient, non-BTH case 8, serum3: after lamivudine, 3 months after serum 2 C 1 344 180M,204V,267Q,269L
AB195952 Japan:Ehime     genotype C; Japanese patient, non-BTH case 9, serum1: before lamivudine C 1 344 223A,256C,267Q,326I
AB195953 Japan:Ehime     genotype C; Japanese patient, non-BTH case 9, serum2: after lamivudine, peak of HBV-DNA C 1 344 80I,204I,223A,256C,267Q,326I
AB195954 Japan:Ehime     genotype C; Japanese patient, non-BTH case 9, serum3: after lamivudine, 3 months after serum 2 C 1 344 80I,204I,223A,256C,267Q,326I
AB195955 Japan:Ehime     genotype C; Japanese patient, non-BTH case 10,serum 1: before lamivudine C 1 344 124H,128A,271H
AB195956 Japan:Ehime     genotype C; Japanese patient, non-BTH case 10,serum 2: after lamivudine, peak of HBV-DNA C 1 344 9Y,124H,128A,180M,204V,224V,229V,271H,318R
AB195957 Japan:Ehime     genotype C; Japanese patient, non-BTH case 10,serum 3: after lamivudine, 3 months after serum 2 C 1 344 9Y,124H,128A,180M,204V,224V,229V,271H,318R

Team

Resources